PT  - JOURNAL ARTICLE
AU  - Binquan Luan
AU  - Tien Huynh
TI  - Insights on SARS-CoV-2’s Mutations for Evading Human Antibodies: Sacrifice and Survival
AID  - 10.1101/2021.02.06.430088
DP  - 2021 Jan 01
TA  - bioRxiv
PG  - 2021.02.06.430088
4099  - http://biorxiv.org/content/early/2021/02/07/2021.02.06.430088.short
4100  - http://biorxiv.org/content/early/2021/02/07/2021.02.06.430088.full
AB  - Recent mutations on the receptor binding domain (RBD) of the SARS-CoV-2’s spike protein have been manifested as the major cause of the wide and rapid spread of the virus. Especially, the variant B.1.351 in South Africa with the hallmark of triple mutations (N501Y, K417N and E484K) is worrisome. Quickly after the outbreak of this new variant, several studies showed that both N501Y and E484K can enhance the binding between RBD and the human ACE2 receptor. However, the mutation K417N seems to be unfavorable because it removes one interfacial salt-bridge. So far, it is still not well understood why the K417N mutation is selected in the viral evolution. Here, we show that despite the loss in the binding affinity (1.48 kcal/mol) between RBD and ACE2 the K417N mutation abolishes a buried interfacial salt-bridge between RBD and the neutralizing antibody CB6 and thus substantially reduces their binding energy by 9.59 kcal/mol, facilitating the variants to efficiently elude CB6 (as well as many other antibodies). Thus, when proliferating from person to person the virus might have adapted to the human immune system through evasive mutations. Taking into account limited and relevant experimental works in the field, we show that our theoretical predictions are consistent with existing experimental findings. By harnessing the revealed molecular mechanism for variants, it becomes feasible to redesign therapeutic antibodies accordingly to make them more efficacious.Competing Interest StatementThe authors have declared no competing interest.